Pulmatrix doses first patient in Ph1 Pulmazole trial
Pulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole. The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix doses first patient in Ph1 Pulmazole trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

8th Advances Against Aspergillosis Conference Round-Up
Mon, 02/05/2018 - 14:02News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - February 5, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

Announcing the Launch of the World Aspergillosis Day Feb 1st
Wed, 01/31/2018 - 16:21News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Announcing the Launch of World Aspergillosis Day Feb 1st
Wed, 01/31/2018 - 16:21News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Global health improvement targets announced on World Aspergillosis Day
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 31, 2018 Category: Respiratory Medicine Authors: GAtherton Source Type: news

Global health improvement targets announced on World Aspergillosis Day Feb. 1st, 2018
(Goodwork) Aspergillosis, lung and sinus disease caused by the fungus Aspergillus, affects around 15 million people and kills over 1 million each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial
The UK Medicines and Healthcare Products Regulatory Agency has given Pulmatrix (NSDQ:PULM) the go-ahead to launch its first-in-human study for an inhaled formulation of the anti-fungal drug, itraconazole. The company is evaluating its drug, Pulmazole, as a treatment for allergic bronchopulmonary aspergillosis in patients with asthma. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix wins EU nod for inhaled dry-powder anti-fungal trial appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Pulmatrix Inc. Source Type: news

Invasive Aspergillosis in Heart Transplant Recipients
Wed, 01/03/2018 - 12:08News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - January 3, 2018 Category: Respiratory Medicine Authors: ROrritt Source Type: news

First CPAnet symposium identifies four key research areas for chronic pulmonary aspergillosis
Thu, 11/16/2017 - 15:40News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 16, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

ImmunoPET: the future of lung scans in aspergillosis?
Wed, 11/15/2017 - 11:48News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 15, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Vitamin D deficiency and aspergillosis
Mon, 11/06/2017 - 17:31News blog (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - November 6, 2017 Category: Respiratory Medicine Authors: BethBradshaw Source Type: news

Hologic to retain CEO MacMillan | Personnel Moves – November 3, 2017
Hologic (NSDQ:HOLX) said this week its current prez and CEO Stephen MacMillan will stay on with the company, resolving rumors that he may depart it to take up the corner office at Zimmer Biomet (NYSE:ZBH). In an SEC filing, the Marlborough, Mass.-based company’s board said it approved a special “performance-based retention equity grant” to MacMillan after he had begun to receive interest from other medical device firms. “Mr. MacMillan has led a dramatic turnaround of Hologic since joining in December 2013. The company’s performance has increased significantly under his leadership and he perso...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News ConMed Corp. Hologic Invacare kentimaging Meritech Capital Partners Pulmatrix Inc. Sanofi-Aventis Smith & Nephew Tissue Regenix zimmerbiomet Source Type: news